TABLE OF CONTENTS		
	
EXECUTIVE SUMMARY		
	•	Objective	
	•	Market scenario	
	
1 INTRODUCTION	
	1.1	Key take-aways	
	1.2	Report description	
	1.3	Markets covered	
	1.4	Research methodology	
	1.5	Stakeholders	
	
2	SUMMARY	
	
3	MARKET OVERVIEW	
	3.1	Market segmentation	
	3.2	High throughput screening & bioanalytical instruments leading the market	
	3.3	Patent analysis	
	
4	DRIVING FACTOR ANALYSIS	
	4.1	Drivers	
		4.1.1	Contract research boosting technology adoption	
		4.1.2	Collaborations between academia & pharmaceutical industry	
		4.1.3	Increased necessity for ADME/toxicity technologies	
	4.2	Opportunities	
		4.2.1	Offshoring scenario for drug discovery	
	
5	HIGH THROUGHPUT SCREENING	
	5.1	Introduction	
	5.2	Market overview	
	5.3	Burning issues & winning imperatives	
		5.3.1	Increasing participation from academic research	
		5.3.2	High throughput screening set up: pharmaceutical vs academic	
	5.4	Ultra high throughput screening	
	5.5	Robotics & automation	
	5.6	Miniaturization	
	5.7	High content screening	
		5.7.1	Opportunities	
			5.7.1.1	GPCR drug discovery	
	5.8	Cell based assays	
	
6	BIOANALYTICAL INSTRUMENTS	
	6.1	Introduction	
	6.2	Burning issues & trends	
		6.2.1	Pharmaceutical industry a major end client	
		6.2.2	Agilent penetration in bioanalytical instruments market	
		6.2.3	Outsourcing scenario	
	6.3	Mass spectrometry	
		6.3.1	Upcoming technology - Maldi-QMS	
	6.4	Microplate readers	
	6.5	Nuclear magnetic resonance	
	6.6	Chemotherapy instruments	
	
7	Pharmacogenomics	
	7.1	Introduction	
	7.2	Pharmacogenomics applications in drug development	
	7.3	Burning issues	
		7.3.1	Commercial hurdles in drug development	
			7.3.1.1	Cost issues in clinical development	
			7.3.1.2	FDA approval	
		7.3.1.3	Ethical issues	
		7.3.2	Pharmacogenomics for drug reintroduction	
		7.3.3	Pharmacogenomics applications in existing drugs	
	7.4	Key trends in the pharmacogenomics technology market	
		7.4.1	Regulatory initiatives boosting adoption for pharmacogenomics technology	
		7.4.2	Rise in pharmacogenomics consortia boost technology based research	
		7.4.3	Increasing importance of databases	
	7.5	Future prospects for pharmacogenomics technology research	
	7.6	Pharmacogenomics products: pricing effects	
		7.6.1	Case study: high priced herceptin	
		7.6.2	Pharmacogenomics cost effectiveness	
	7.7	Pharmacogenomics technology: short & long term benefits	
		7.7.1	Improvement in patient safety	
		7.7.2	Increase in drug effectiveness	
		7.7.3	Selection of medication for chronic diseases	
		7.7.4	Better economic efficiency for the healthcare system	
		7.7.5	Improved patient access to drugs	
	
8	COMBINATORIAL CHEMISTRY	
	8.1	Introduction	
	8.2	Market drivers	
		8.2.1	Technological advances boost adoption of combinatorial chemistry	
		8.2.2	Process enhancement results in better compounds	
		8.2.3	Collaborative approach	
		8.2.4	Need for novel compounds acts as market opportunity	
	8.3	Stakeholders characteristics	
	8.4	Burning issues	
	8.5	Key trends and market boosters	
		8.5.1	Increased recognition of combinatorial chemistry technology	
		8.5.2	Faster drug discovery	
	
9	GENOMICS	
	9.1	Introduction	
	9.2	Winning imperatives	
		9.2.1	Reducing cost for whole genome sequencing	
	9.3	Functional genomics	
	9.4	Structural genomics	
	
10	BIOCHIPS	
	10.1	Introduction	
	10.2	Burning issues	
		10.2.1	Business trends	
		10.2.2	Patent disputes	
		10.2.3	Competition	
	10.3	Industry trends	
		10.3.1	Next generation technology: microfluidics with CD-ROM	
		10.3.2	Biochips in biomarker development	
		10.3.3	Outsourcing the biochip technology	
	10.4	DNA microarrays	
		10.4.1	Market drivers	
			10.4.1.1	Increased utilization in complex diseases	
			10.4.1.2	Sequence data proliferation	
			10.4.1.3	Easy-access programs	
	10.5	Lab on a chip	
		10.5.1.	New technology & cost saving by lab on a chip boost the market	
	10.6	Proteomics microarrays	
		10.6.1	Burning issues and trends	
			10.6.1.1	Technical lags	
			10.6.1.2	Human protein microarray for multiple protein analysis	
	
11	BIOINFORMATICS	
	11.1	Introduction	
	11.2	Burning issues and trends	
		11.2.1	Outsourcing	
		11.2.2	Allocation of grants	
	
12	PROTEOMICS	
	12.1	Introduction	
	12.2	Industry trends	
		12.2.1	Funding for proteomics research	
		12.2.2	Proteomics in anti cancer drug discovery	
	12.3	Two dimensional gel electrphoresis- 2DGE	
	12.4	Two-hybrid systems	
	
13	RNAI	
	13.1	Technology overview	
	13.2	Winning imperatives	
		13.2.1	Core competency acquisition	
	13.3	Opportunity in RNAi drug discovery	
		13.3.1	RNAi based cholesterol drugs	
		13.3.2	Cancer drugs	
	13.4	SiRNA	
	13.5	MiRNAS	
	13.6	Other RNAi technologies	
	
14	NANOTECHNOLOGY	
	14.1	Introduction	
	14.2	Healthcare application areas for nanotechnology	
		14.2.1	Biomedical research	
		14.2.2	Therapeutics	
		14.2.3	Diagnostics	
	14.3	Burning issues and trends	
		14.3.1	Regulatory & health issues	
		14.3.2	Increase in funding	
	14.4	Atomic force microscopy (AFM)	
	14.5	Nano-mass spectroscopy	
	14.6	Dip-pen Nanolithography	
	
15	GEOGRAPHICAL ANALYSIS	
	15.1	Introduction	
	15.2	North America	
	15.3	Europe	
	15.4	Asia	
	15.5	ROW	
	
16	COMPETITIVE LANDSCAPE	
	16.1	Market share for drug discovery technologies	
	16.2	Agreements & collaborations	
	16.3	New product launch	
	16.4	End clients for top 10 drug discovery technologies	
	
17	COMPANY PROFILES	
17.1	ABBOTT LABORATORIES INC.
	17.1.1	Overview
	17.1.2	Primary business
	17.1.3	Strategy
	17.1.4	Developments
17.2	AFFYMETRIX INC.
	17.2.1	Overview
	17.2.2	Primary business
	17.2.3	Strategy
	17.2.4	Developments
17.3	AGILENT TECHNOLOGIES INC.
	17.3.1	Overview
	17.3.2	Primary business
	17.3.3	Strategy
	17.3.4	Developments
17.4	ALBANY MOLECULAR RESEARCH INC.
	17.4.1	Overview
	17.4.2	Primary business
	17.4.3	Strategy
	17.4.4	Developments
17.5	ARQULE INC.
	17.5.1	Overview
	17.5.2	Primary business
	17.5.3	Strategy
	17.5.4	Developments
17.6	ASTRAZENECA PLC.
	17.6.1	Overview
	17.6.2	Primary business
	17.6.3	Strategy
	17.6.4	Developments
17.7	BIO-RAD LABORATORIES INC.
	17.7.1	Overview
	17.7.2	Primary business
	17.7.3	Strategy
	17.7.4	Developments
17.8	CALIPER LIFE SCIENCES INC.
	17.8.1	Overview
	17.8.2	Primary business
	17.8.3	Strategy
	17.8.4	Developments
17.9	CELERA CORP
	17.9.1	Overview
	17.9.2	Primary business
	17.9.3	Strategy
	17.9.4	Developments
17.10	CHARLES RIVER LABORATORIES INTERNATIONAL INC.
	17.10.1	Overview
	17.10.2	Primary business
	17.10.3	Strategy
	17.10.4	Developments
17.11	CHEMBRIDGE CORP
	17.11.1	Overview
	17.11.2	Primary business
	17.11.3	Strategy
	17.11.4	Developments
17.12	EVOTEC AG
	17.12.1	Overview
	17.12.2	Primary business
	17.12.3	Strategy
	17.12.4	Developments
17.13	F. HOFFMANN-LA ROCHE LTD.
	17.13.1	Overview
	17.13.2	Primary business
	17.13.3	Strategy
	17.13.4	Developments
17.14	GYROS AB
	17.14.1	Overview
	17.14.2	Primary business
	17.14.3	Strategy
	17.14.4	Developments
17.15	INCYTE CORP
	17.15.1	Overview
	17.15.2	Primary business
	17.15.3	Strategy
	17.15.4	Developments
17.16	LIFE TECHNOLOGIES CORP
	17.16.1	Overview
	17.16.2	Primary business
	17.16.3	Strategy
	17.16.4	Developments
17.17	SHIMADZU CORP
	17.17.1	Overview
	17.17.2	Primary business
	17.17.3	Strategy
	17.17.4	Developments
17.18	PERKINELMER INC.
	17.18.1	Overview
	17.18.2	Primary business
	17.18.3	Strategy
	17.18.4	Developments
17.19	SIGMA-ALDRICH CORP
	17.19.1	Overview
	17.19.2	Primary business
	17.19.3	Strategy
	17.19.4	Developments
17.20	TECAN GROUP LTD.
	17.20.1	Overview
	17.20.2	Primary business
	17.20.3	Strategy
	17.20.4	Developments
17.21	THERMO FISHER SCIENTIFIC INC.
	17.21.1	Overview
	17.21.2	Primary business
	17.21.3	Strategy
	17.21.4	Developments
	
APPENDIX		
	•	U.S. patents	
	•	EUROPE patents	
	•	JAPAN patents	

	
LIST OF TABLES		

1	Global top 10 drug discovery technologies market 2008 – 2015 ($Million)	
2	Estimated time saving by CRO in clinical trials	
3	Global high throughput screening market, by products 2008 – 2015 ($Million)	
4	High throughput screening market, by geography 2008 – 2015 ($Million)	
5	HTS infrastructural/resource comparison for pharmaceutical and academic centers	
6	Ultra high throughput screening market, by geography 2008 – 2015 ($Million)	
7	Robotics and automation market, by geography 2008 – 2015 ($Million)	
8	Miniaturization market, by geography 2008 – 2015 ($Million)	
9	High content screening market, by geography 2008 – 2015 ($Million)	
10	Cell based assays market, by geography 2008 – 2015 ($Million)	
11	Global bioanalytical instruments market, by products 2008 – 2015 ($Million)	
12	Bioanalytical instruments market, by geography 2008 – 2015 ($Million)	
13	Global mass spectrometry market, by products 2008 – 2015 ($Million)	
14	Mass spectrometry market, by geography 2008 – 2015 ($Million)	
15	Microplate Readers Market, By Geography 2008 – 2015 ($Million)	
16	NMR market, by geography 2008 – 2015 ($Million)	
17	Chemotherapy instruments market, by geography 2008 – 2015 ($Million)	
18	Pharmacogenomics market, by geography 2008 – 2015 ($Million)	
19	Combinatorial chemistry market, by geography 2008 – 2015 ($Million)	
20	Cost comparison between traditional and combinatorial chemistry	
21	Global genomics market, by products 2008 – 2015 ($Million)	
22	Genomics market, by geography 2008 – 2015 ($Million)	
23	Functional genomics market, by geography 2008 – 2015 ($Million)	
24	Structural genomics market, by geography 2008 – 2015 ($Million)	
25	Global biochips market, by segment 2008 – 2015 ($Million)	
26	Biochips market, by geography 2008 – 2015 ($Million)	
27	Patent disputes within the biochips market	
28	DNA microarrays market, by geography 2008 – 2015 ($Million)	
29	Lab on a chip market, by geography 2008 – 2015 ($Million)	
30	Proteomics microarrays market, by geography 2008 – 2015 ($Million)	
31	Global bioinformatics market, by products 2008 – 2015 ($Million)	
32	Bioinformatics market, by geography 2008 – 2015 ($Million)	
33	Global proteomics market, by products2008 – 2015 ($Million)	
34	Proteomics market, by geography 2008 – 2015 ($Million)	
35	2DGE market, by geography 2008 – 2015 ($Million)	
36	Two hybrid systems market, by geography 2008 – 2015 ($Million)	
37	Global RNAi market, by products 2008 – 2015 ($Million)	
38	RNAi market, by geography 2008 – 2015 ($Million)	
39	SiRNA market, by geography 2008 – 2015 ($Million)	
40	MiRNA market, by geography 2008 – 2015 ($Million)	
41	Global other RNAi technologies market, by products 2008 – 2015 ($Million)	
42	Other RNAi technologies market, by geography 2008 – 2015 ($Million)	
43	Global nanotechnology market, by products 2008 – 2015 ($Million)	
44	Nanotechnology market, by geography 2008 – 2015 ($Million)	
45	Comparison of AFM technology with other microscopy technology	
46	Atomic force microscopy market, by geography 2008 – 2015 ($Million)	
47	Nano-mass spectroscopy market, by geography 2008 – 2015 ($Million)	
48	Dip-pen Nanolithography market, by geography 2008 – 2015 ($Million)	
49	North American top 10 drug discovery technologies market 2008 – 2015 ($Million)	
50	European top 10 drug discovery technologies market 2008 – 2015 ($Million)	
51	Asian top 10 drug discovery technologies market 2008 – 2015 ($Million)	
52	RoW top 10 drug discovery technologies market 2008 – 2015 ($Million)	
53	Agreements and collaborations (2009 – 2010)	
54	New product development (2009 – 2010)	

	
LIST OF FIGURES		
1	Revenue analysis for top 10 drug discovery technologies	
2	Top 10 drug discovery technologies market segmentation	
3	Relative market scenario (2010)	
4	Patent analysis by geography	
5	Patent analysis by competitors 2005 – 2010	
6	High throughput screening in drug discovery	
7	Approximate industrial demand for bioanalytical instruments (2010)	
8	Cost saving in comparison with high throughput screening	
9	Approximate end client share for microplate readers	
10	Drug development process and pharmacogenomics applications	
11	Future advancements in the pharmacogenomics research	
12	Cost associated with pharmacogenomics based tests	
13	Long term goals/benefits for pharmacogenomics	
14	Dollar value offered, by technology providers	
15	Time and cost saving by implementation of combinatorial chemistry	
16	Reducing costs for whole genome sequencing	
17	Major end clients for biochip technology market	
18	Historical data for DNA microarray based collaborations	
19	Applications of lab-on-a-chip technology in drug discovery	
20	MiRNA research efforts	
21	Applications areas of MiRNA	
22	MiRNA in drug discovery	
23	Nanotechnology applications	
24	Global market for top 10 drug discovery technologies	
25	Approximate market share for overall drug discovery technologies	
26	Approximate end client share for top 10 drug discovery technologies